man in an outdoor settingman in an outdoor settingteal triangle graphic

Medicines & Focus

Innovation Focused
on Complex Diseases


Therapeutic Areas of Focus

We are inspired by the courage and determination of individuals living with complicated and often difficult-to-treat diseases. We have a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders.


Disease Areas

Addiction

We have been at the forefront of addiction medicine for more than a decade, seeking to help people living with alcohol dependence and opioid dependence.

Serious Mental Illness

We are committed to addressing unmet needs in serious mental illness through the development of therapeutic options to support people living with schizophrenia and bipolar I disorder.

Sleep Disorders

We are actively researching potential new treatment options for people living with narcolepsy and other sleep disorders, which impair regulation of the sleep-wake cycle and can take an immense toll on daily life.

We Develop Innovative Medicines 

Alkermes’ technologies and discoveries have contributed to the development of medicines that have helped shape the treatment landscape, and form the basis for our current investigational products, in a range of disease areas.

Proprietary U.S. Medicines

Our mission to make innovative medicines that may help address unmet patient needs underlies our work. Our portfolio of proprietary commercial products focuses on chronic, highly prevalent conditions that represent some of the most challenging health issues of our time.


Our proprietary U.S. medicines

Product Candidates in Development

Our research and development efforts are focused on the pursuit of potential new medicines that build on our heritage in neuroscience.




Our R&D efforts

Third-Party Medicines

Our proprietary technologies are incorporated into third-party medicines that are commercialized by global pharmaceutical companies for people living with a range of serious diseases.
Learn more about third-party medicines that utilize our proprietary technologies.

U.S. medicines   EU medicines

Man in a conference room at Alkermesteal triangle graphic

Commitment to patients runs very deep at Alkermes. It starts when we discover new ideas in our labs, continues as we conduct clinical trials, make our medicines, educate stakeholders about unmet needs and support those who take our medicines.